Here you will find articles that keep you up to date on the newest AML research that AML experts are recruiting for. AML research studies called clinical trials are all about drug development. Drugs must go through many phases of testing to receive FDA approval in order to be prescribed to patients by doctors. Joining a clinical trial for your AML has the potential to provide you with cutting-edge treatment that is not yet widely available to the general public.
In addition to drug development, AML research aims to answer important questions like "what is AML?", "what causes AML?", "is AML genetic?" and "how do we improve AML survival?"
There are over 300 AML research trials actively recruiting patients, which is more than any other leukemia. These articles will keep you informed on the latest clinical trials that are recruiting and the types of new drug therapies that are being studied for the treatment of AML.
AML Clinical Trials—September 23, 2021
VOR33, a cell therapy candidate intended to replace the standard of care in stem cell transplant, receives fast track designation from the FDA, making this therapy eligible for priority review and accelerated approval if certain conditions are met. This designation demonstrates the FDA's acknowledgment that this engineered stem cell product could fulfill a major unmet medical need for those with AML at a high risk of relapse.
AML Clinical Trials—August 19, 2021
We want to keep you up to date on what's going on in AML research. Here is a compilation of the major research topics experts are exploring in 2021.
AML Clinical Trials—July 22, 2021
Patients undergoing chemotherapy for AML are at a high risk for infection, which is the leading cause of complications during induction therapy. Romyelocel-L is a treatment of ready-made human immune cells that has been shown to prevent infections in patients treated for AML who have weakened immune systems, according to the results of a phase 2 trial published in the Journal of Clinical Oncology.
AML Clinical Trials—June 24, 2021
Today, the first patient in the Phase 1b KOMET-001 trial was given KO-359, an oral investiagional drug candidate for patients with relapsed or refractory AML who have NPM1 mutations or KMT2A rearrangements. This trial is currently recruiting patients. You can check out the details on our clinicial trial finder by clicking the link at the end of this article.